|
Rare neoplastic disorders (N = 269)
|
Other rare conditions (N = 461)
|
---|
Product type
|
Synthetic/extractive agent
|
53.5% (144)
|
53.8% (248)
|
Biotechnology
|
46.5% (125)
|
46.2% (213)
|
Applicant categorization
|
Academia/Public body
|
0% (0)a
|
4% (20)a
|
Consulting
|
9% (25)
|
11% (52)
|
Physical person
|
2% (6)a
|
6% (27)a
|
SME
|
56% (150)a
|
47% (216)a
|
Intermediate sized company
|
13% (35)
|
16% (75)
|
Large Pharma
|
13% (35)a
|
7% (31)a
|
Very large Pharma
|
7% (18)
|
9% (40)
|
Prevalence segmentation
|
< 1/10,000
|
19% (51)
|
47.7%(220)
|
1–3/10,000
|
69.1% (186)a
|
41.4% (191)a
|
> 3/10,000
|
11.9% (32)a
|
10.8% (50)a
|
Consideration of significant benefit criterion
|
Yes
|
75.1% (202)a
|
44.3% (204)a
|
-
aIndicates difference at 0.05 level based on Chi2 test